Ignite Creation Date:
2024-07-17 @ 11:04 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06470178
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-17
Brief Title:
A Real-World Study of NeoadjuvantConversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
Sponsor:
Wuhan University
Organization:
Wuhan University
Study Overview
Official Title:
A Real-World Study of NeoadjuvantConversion Therapy for Locally Advanced or Metastatic Colorectal Cancer With Chemotherapy Combined With Anti-Angiogenic Targeted Agents
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advancedadvanced colorectal cancer has not yet been reported This study aims to observe the efficacy and safety of fruquintinib combined with chemotherapy in neoadjuvant or conversion therapy for colorectal cancer patients in the real world
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None